

M Juliana Mcelrath

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8271188/publications.pdf>

Version: 2024-02-01

148
papers

18,231
citations

30070

54
h-index

15266

126
g-index

161
all docs

161
docs citations

161
times ranked

21571
citing authors

#	ARTICLE	IF	CITATIONS
1	Homologous and Heterologous Covid-19 Booster Vaccinations. <i>New England Journal of Medicine</i> , 2022, 386, 1046-1057.	27.0	418
2	Whole-blood cytokine secretion assay as a high-throughput alternative for assessing the cell-mediated immunity profile after two doses of an adjuvanted SARS-CoV-2 recombinant protein vaccine candidate. <i>Clinical and Translational Immunology</i> , 2022, 11, e1360.	3.8	14
3	Transcriptional correlates of malaria in RTS,S/AS01-vaccinated African children: a matched case-control study. <i>ELife</i> , 2022, 11, .	6.0	4
4	Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: A randomised, placebo-controlled, multicentre Phase II clinical trial. <i>PLoS Medicine</i> , 2022, 19, e1003865.	8.4	27
5	Systems analysis of immune responses to attenuated <i>P. falciparum</i> malaria sporozoite vaccination reveals excessive inflammatory signatures correlating with impaired immunity. <i>PLoS Pathogens</i> , 2022, 18, e1010282.	4.7	9
6	Targeting an alternate Wilms tumor antigen 1 peptide bypasses immunoproteasome dependency. <i>Science Translational Medicine</i> , 2022, 14, eabg8070.	12.4	12
7	Characterization of a vaccine-elicited human antibody with sequence homology to VRC01-class antibodies that binds the C1C2 gp120 domain. <i>Science Advances</i> , 2022, 8, eabm3948.	10.3	1
8	Analysis of the HIV Vaccine Trials Network 702 Phase 2b-3 HIV-1 Vaccine Trial in South Africa Assessing RV144 Antibody and T-Cell Correlates of HIV-1 Acquisition Risk. <i>Journal of Infectious Diseases</i> , 2022, 226, 246-257.	4.0	11
9	Th2-Biased Transcriptional Profile Predicts HIV Envelope-Specific Polyfunctional CD4+ T Cells That Correlated with Reduced Risk of Infection in RV144 Trial. <i>Journal of Immunology</i> , 2022, 209, 526-534.	0.8	3
10	Generation of a cost-effective cell line for support of high-throughput isolation of primary human B cells and monoclonal neutralizing antibodies. <i>Journal of Immunological Methods</i> , 2021, 488, 112901.	1.4	9
11	mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection. <i>Science</i> , 2021, 372, 1413-1418.	12.6	468
12	Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120-MF59 in Adults. <i>New England Journal of Medicine</i> , 2021, 384, 1089-1100.	27.0	144
13	Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition. <i>New England Journal of Medicine</i> , 2021, 384, 1003-1014.	27.0	270
14	Innate immune signatures to a partially-efficacious HIV vaccine predict correlates of HIV-1 infection risk. <i>PLoS Pathogens</i> , 2021, 17, e1009363.	4.7	19
15	Meta-analysis of HIV-1 vaccine elicited mucosal antibodies in humans. <i>Npj Vaccines</i> , 2021, 6, 56.	6.0	7
16	Distinct populations of antigen specific tissue resident CD8 T cells in human cervix mucosa. <i>JCI Insight</i> , 2021, 6, .	5.0	10
17	Buprenorphine Increases HIV-1 Infection In Vitro but Does Not Reactivate HIV-1 from Latency. <i>Viruses</i> , 2021, 13, 1472.	3.3	8
18	AIDSVAX protein boost improves breadth and magnitude of vaccine-induced HIV-1 envelope-specific responses after a 7-year rest period. <i>Vaccine</i> , 2021, 39, 4641-4650.	3.8	1

#	ARTICLE	IF	CITATIONS
19	Isolation and characterization of cross-neutralizing coronavirus antibodies from COVID-19+ subjects. Cell Reports, 2021, 36, 109353.	6.4	95
20	Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells. Cell Reports Medicine, 2021, 2, 100354.	6.5	316
21	Rectal tissue and vaginal tissue from intravenous VRC01 recipients show protection against ex vivo HIV-1 challenge. Journal of Clinical Investigation, 2021, 131, .	8.2	17
22	Machine learning identifies molecular regulators and therapeutics for targeting SARS-CoV-2-induced cytokine release. Molecular Systems Biology, 2021, 17, e10426.	7.2	18
23	HIV-1 Nucleic Acids Identify Rectal HIV Exposures in Self-Collected Rectal Swabs, Whereas Y-Chromosome Single Tandem Repeat Mixtures Are Not Reliable Biomarkers of Condomless Receptive Anal Intercourse. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, 88, 138-148.	2.1	0
24	Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: A randomised, placebo-controlled Phase II clinical trial in Africa. PLoS Medicine, 2021, 18, e1003813.	8.4	34
25	Sequence and vector shapes vaccine induced antibody effector functions in HIV vaccine trials. PLoS Pathogens, 2021, 17, e1010016.	4.7	1
26	Calibration of two validated SARS-CoV-2 pseudovirus neutralization assays for COVID-19 vaccine evaluation. Scientific Reports, 2021, 11, 23921.	3.3	44
27	Phase 1 Human Immunodeficiency Virus (HIV) Vaccine Trial to Evaluate the Safety and Immunogenicity of HIV Subtype C DNA and MF59-Adjuvanted Subtype C Envelope Protein. Clinical Infectious Diseases, 2020, 72, 50-60.	5.8	15
28	Activated PD-1+ CD4+ T cells represent a short-lived part of the viral reservoir and predict poor immunologic recovery upon initiation of ART. Aids, 2020, 34, 197-202.	2.2	6
29	Use of adenovirus type-5 vectored vaccines: a cautionary tale. Lancet, The, 2020, 396, e68-e69.	13.7	50
30	Treatment with Commonly Used Antiretroviral Drugs Induces a Type I/III Interferon Signature in the Gut in the Absence of HIV Infection. Cell Reports Medicine, 2020, 1, 100096.	6.5	10
31	Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study. Lancet HIV, the, 2020, 7, e688-e698.	4.7	58
32	Rapid Collection of Human Rectal Secretions Using OriCol Devices Is Suitable for Measurement of Mucosal Ig without Blood Contamination. Journal of Immunology, 2020, 205, 2312-2320.	0.8	0
33	COVID-19 and the Path to Immunity. JAMA - Journal of the American Medical Association, 2020, 324, 1279.	7.4	156
34	Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation. Immunity, 2020, 53, 98-105.e5.	14.3	376
35	A phase 1b randomized study of the safety and immunological responses to vaccination with H4:IC31, H56:IC31, and BCG revaccination in Mycobacterium tuberculosis-uninfected adolescents in Cape Town, South Africa. EClinicalMedicine, 2020, 21, 100313.	7.1	52
36	Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines. PLoS Medicine, 2020, 17, e1003038.	8.4	27

#	ARTICLE	IF	CITATIONS
37	HIV-1 Vaccine Sequences Impact V1V2 Antibody Responses: A Comparison of Two Poxvirus Prime gp120 Boost Vaccine Regimens. <i>Scientific Reports</i> , 2020, 10, 2093.	3.3	17
38	Mechanisms of Endogenous HIV-1 Reactivation by Endocervical Epithelial Cells. <i>Journal of Virology</i> , 2020, 94, .	3.4	9
39	Robust antibody and cellular responses induced by DNA-only vaccination for HIV. <i>JCI Insight</i> , 2020, 5, .	5.0	25
40	Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trials. <i>PLoS Medicine</i> , 2020, 17, e1003117.	8.4	8
41	Landscapes of binding antibody and T-cell responses to pox-protein HIV vaccines in Thais and South Africans. <i>PLoS ONE</i> , 2020, 15, e0226803.	2.5	16
42	Response to Guo et al.'s Letter to the Editor. <i>Biostatistics</i> , 2019, 20, 363-365.	1.5	0
43	CXCR3 enables recruitment and site-specific bystander activation of memory CD8+ T cells. <i>Nature Communications</i> , 2019, 10, 4987.	12.8	68
44	Rapid Boosting of HIV-1 Neutralizing Antibody Responses in Humans Following a Prolonged Immunologic Rest Period. <i>Journal of Infectious Diseases</i> , 2019, 219, 1755-1765.	4.0	7
45	Fc Gamma Receptor Polymorphisms Modulated the Vaccine Effect on HIV-1 Risk in the HVTN 505 HIV Vaccine Trial. <i>Journal of Virology</i> , 2019, 93, .	3.4	26
46	Immune correlates of the Thai RV144 HIV vaccine regimen in South Africa. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	46
47	Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trial. <i>Lancet HIV</i> , 2019, 6, e737-e749.	4.7	43
48	Broad and Potent Neutralizing Antibodies Recognize the Silent Face of the HIV Envelope. <i>Immunity</i> , 2019, 50, 1513-1529.e9.	14.3	85
49	OMIP056: Evaluation of Human Conventional T Cells, Donor Unrestricted T Cells, and NK Cells Including Memory Phenotype by Intracellular Cytokine Staining. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2019, 95, 722-725.	1.5	14
50	Integrated systems approach defines the antiviral pathways conferring protection by the RV144 HIV vaccine. <i>Nature Communications</i> , 2019, 10, 863.	12.8	27
51	Antigenic competition in CD4 ⁺ T cell responses in a randomized, multicenter, double-blind clinical HIV vaccine trial. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	18
52	Vaccine-Induced Antibodies Mediate Higher Antibody-Dependent Cellular Cytotoxicity After Interleukin-15 Pretreatment of Natural Killer Effector Cells. <i>Frontiers in Immunology</i> , 2019, 10, 2741.	4.8	25
53	BCG revaccination boosts adaptive polyfunctional Th1/Th17 and innate effectors in IGRA+ and IGRA- Indian adults. <i>JCI Insight</i> , 2019, 4, .	5.0	48
54	Antibody Fc effector functions and IgG3 associate with decreased HIV-1 risk. <i>Journal of Clinical Investigation</i> , 2019, 129, 4838-4849.	8.2	95

#	ARTICLE	IF	CITATIONS
55	DNA priming and gp120 boosting induces HIV-specific antibodies in a randomized clinical trial. Journal of Clinical Investigation, 2019, 129, 4769-4785.	8.2	27
56	An Antibody Targeting the Fusion Machinery Neutralizes Dual-Tropic Infection and Defines a Site of Vulnerability on Epstein-Barr Virus. Immunity, 2018, 48, 799-811.e9.	14.3	104
57	Modification of the Association Between T-Cell Immune Responses and Human Immunodeficiency Virus Type 1 Infection Risk by Vaccine-Induced Antibody Responses in the HVTN 505 Trial. Journal of Infectious Diseases, 2018, 217, 1280-1288.	4.0	32
58	Rank-based two-sample tests for paired data with missing values. Biostatistics, 2018, 19, 281-294.	1.5	19
59	Safety and tolerability of HIV-1 multiantigen pDNA vaccine given with IL-12 plasmid DNA via electroporation, boosted with a recombinant vesicular stomatitis virus HIV Gag vaccine in healthy volunteers in a randomized, controlled clinical trial. PLoS ONE, 2018, 13, e0202753.	2.5	39
60	Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial. Lancet HIV, 2018, 5, e366-e378.	4.7	86
61	Cryopreservation of human mucosal tissues. PLoS ONE, 2018, 13, e0200653.	2.5	14
62	Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19). Lancet, 2018, 392, 232-243.	13.7	269
63	Innovative approaches to track lymph node germinal center responses to evaluate development of broadly neutralizing antibodies in human HIV vaccine trials. Vaccine, 2018, 36, 5671-5677.	3.8	11
64	Vaccination establishes clonal relatives of germinal center T cells in the blood of humans. Journal of Experimental Medicine, 2017, 214, 2139-2152.	8.5	106
65	Controlled Human Malaria Infection Leads to Long-Lasting Changes in Innate and Innate-like Lymphocyte Populations. Journal of Immunology, 2017, 199, 107-118.	0.8	45
66	Higher T-Cell Responses Induced by DNA/rAd5 HIV-1 Preventive Vaccine Are Associated With Lower HIV-1 Infection Risk in an Efficacy Trial. Journal of Infectious Diseases, 2017, 215, 1376-1385.	4.0	59
67	Adjuvants. Current Opinion in HIV and AIDS, 2017, 12, 278-284.	3.8	27
68	Adenovirus Serotype 5 Vaccination Results in Suboptimal CD4 T Helper 1 Responses in Mice. Journal of Virology, 2017, 91, .	3.4	9
69	DNA Priming Increases Frequency of T-Cell Responses to a Vesicular Stomatitis Virus HIV Vaccine with Specific Enhancement of CD8 ⁺ T-Cell Responses by Interleukin-12 Plasmid DNA. Vaccine Journal, 2017, 24, .	3.1	33
70	Origin and differentiation of human memory CD8 T cells after vaccination. Nature, 2017, 552, 362-367.	27.8	412
71	A randomized controlled safety/efficacy trial of therapeutic vaccination in HIV-infected individuals who initiated antiretroviral therapy early in infection. Science Translational Medicine, 2017, 9, .	12.4	105
72	Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy Trials. Statistical Communications in Infectious Diseases, 2017, 9, .	0.2	62

#	ARTICLE	IF	CITATIONS
73	RTS,S/AS01E Malaria Vaccine Induces Memory and Polyfunctional T Cell Responses in a Pediatric African Phase III Trial. <i>Frontiers in Immunology</i> , 2017, 8, 1008.	4.8	34
74	Immunogenicity of a novel Clade B HIV-1 vaccine combination: Results of phase 1 randomized placebo controlled trial of an HIV-1 GM-CSF-expressing DNA prime with a modified vaccinia Ankara vaccine boost in healthy HIV-1 uninfected adults. <i>PLoS ONE</i> , 2017, 12, e0179597.	2.5	29
75	Sieve analysis of breakthrough HIV-1 sequences in HVTN 505 identifies vaccine pressure targeting the CD4 binding site of Env-gp120. <i>PLoS ONE</i> , 2017, 12, e0185959.	2.5	27
76	Whole genome sequencing of extreme phenotypes identifies variants in CD101 and UBE2V1 associated with increased risk of sexually acquired HIV-1. <i>PLoS Pathogens</i> , 2017, 13, e1006703.	4.7	16
77	In Situ Staining and Laser Capture Microdissection of Lymph Node Residing SIV Gag-Specific CD8+ T cells—A Tool to Interrogate a Functional Immune Response Ex Vivo. <i>PLoS ONE</i> , 2016, 11, e0149907.	2.5	3
78	Neutralization Takes Precedence Over IgG or IgA Isotype-related Functions in Mucosal HIV-1 Antibody-mediated Protection. <i>EBioMedicine</i> , 2016, 14, 97-111.	6.1	47
79	Safety and Immunogenicity of Novel Adenovirus Type 26 and Modified Vaccinia Ankara Vectored Ebola Vaccines. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 1610.	7.4	266
80	HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1. <i>Science</i> , 2016, 352, 997-1001.	12.6	263
81	CXCL13 is a plasma biomarker of germinal center activity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 2702-2707.	7.1	322
82	Selection of HIV vaccine candidates for concurrent testing in an efficacy trial. <i>Current Opinion in Virology</i> , 2016, 17, 57-65.	5.4	14
83	Vaccination With Heterologous HIV-1 Envelope Sequences and Heterologous Adenovirus Vectors Increases T-Cell Responses to Conserved Regions: HVTN 083. <i>Journal of Infectious Diseases</i> , 2016, 213, 541-550.	4.0	28
84	Distinct activation thresholds of human conventional and innate-like memory T cells. <i>JCI Insight</i> , 2016, 1, .	5.0	116
85	Pooled-Peptide Epitope Mapping Strategies Are Efficient and Highly Sensitive: An Evaluation of Methods for Identifying Human T Cell Epitope Specificities in Large-Scale HIV Vaccine Efficacy Trials. <i>PLoS ONE</i> , 2016, 11, e0147812.	2.5	42
86	Cryopreservation of Human Mucosal Leukocytes. <i>PLoS ONE</i> , 2016, 11, e0156293.	2.5	14
87	Transient Peripheral Immune Activation follows Elective Sigmoidoscopy or Circumcision in a Cohort Study of MSM at Risk of HIV Infection. <i>PLoS ONE</i> , 2016, 11, e0160487.	2.5	6
88	Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive Immunization. <i>PLoS Pathogens</i> , 2016, 12, e1005742.	4.7	81
89	MAST: a flexible statistical framework for assessing transcriptional changes and characterizing heterogeneity in single-cell RNA sequencing data. <i>Genome Biology</i> , 2015, 16, 278.	8.8	2,047
90	Identification and visualization of multidimensional antigen-specific T cell populations in polychromatic cytometry data. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2015, 87, 675-682.	1.5	25

#	ARTICLE	IF	CITATIONS
91	Safety and Immunogenicity of a Recombinant Adenovirus Serotype 35-Vectored HIV-1 Vaccine in Adenovirus Serotype 5 Seronegative and Seropositive Individuals. <i>Journal of AIDS & Clinical Research</i> , 2015, 06, .	0.5	17
92	Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized Trials. <i>PLoS ONE</i> , 2015, 10, e0136626.	2.5	23
93	COMPASS identifies T-cell subsets correlated with clinical outcomes. <i>Nature Biotechnology</i> , 2015, 33, 610-616.	17.5	232
94	Use of placebos in Phase 1 preventive HIV vaccine clinical trials. <i>Vaccine</i> , 2015, 33, 749-752.	3.8	2
95	HIV-1 Integration Landscape during Latent and Active Infection. <i>Cell</i> , 2015, 160, 420-432.	28.9	393
96	Diversion of HIV-1 vaccine-induced immunity by gp41-microbiota cross-reactive antibodies. <i>Science</i> , 2015, 349, aab1253.	12.6	191
97	A side-by-side comparison of T cell reactivity to fifty-nine <i>Mycobacterium tuberculosis</i> antigens in diverse populations from five continents. <i>Tuberculosis</i> , 2015, 95, 713-721.	1.9	35
98	HLA class II genes modulate vaccine-induced antibody responses to affect HIV-1 acquisition. <i>Science Translational Medicine</i> , 2015, 7, 296ra112.	12.4	47
99	Plasma Cytokine Levels and Risk of HIV Type 1 (HIV-1) Transmission and Acquisition: A Nested Case-Control Study Among HIV-1 Serodiscordant Couples. <i>Journal of Infectious Diseases</i> , 2015, 211, 1451-1460.	4.0	47
100	HIV-1 Single-Stranded RNA Induces CXCL13 Secretion in Human Monocytes via TLR7 Activation and Plasmacytoid Dendritic Cell-Derived Type I IFN. <i>Journal of Immunology</i> , 2015, 194, 2769-2775.	0.8	49
101	Dissecting Polyclonal Vaccine-Induced Humoral Immunity against HIV Using Systems Serology. <i>Cell</i> , 2015, 163, 988-998.	28.9	326
102	Vaccine-Induced Linear Epitope-Specific Antibodies to Simian Immunodeficiency Virus SIVmac239 Envelope Are Distinct from Those Induced to the Human Immunodeficiency Virus Type 1 Envelope in Nonhuman Primates. <i>Journal of Virology</i> , 2015, 89, 8643-8650.	3.4	42
103	T Cell Responses against Mycobacterial Lipids and Proteins Are Poorly Correlated in South African Adolescents. <i>Journal of Immunology</i> , 2015, 195, 4595-4603.	0.8	27
104	HIV-1 infections with multiple founders are associated with higher viral loads than infections with single founders. <i>Nature Medicine</i> , 2015, 21, 1139-1141.	30.7	50
105	OMIP025: Evaluation of human T- and NK-cell responses including memory and follicular helper phenotype by intracellular cytokine staining. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2015, 87, 289-292.	1.5	36
106	Mucosal effects of tenofovir 1% gel. <i>ELife</i> , 2015, 4, .	6.0	37
107	Optimizing Viable Leukocyte Sampling from the Female Genital Tract for Clinical Trials: An International Multi-Site Study. <i>PLoS ONE</i> , 2014, 9, e85675.	2.5	73
108	HIV-1 Specific IgA Detected in Vaginal Secretions of HIV Uninfected Women Participating in a Microbicide Trial in Southern Africa Are Primarily Directed Toward gp120 and gp140 Specificities. <i>PLoS ONE</i> , 2014, 9, e101863.	2.5	36

#	ARTICLE	IF	CITATIONS
109	Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial Reveals an Association of Nonspecific Interferon- β Secretion with Increased HIV-1 Infection Risk: A Cohort-Based Modeling Study. PLoS ONE, 2014, 9, e108631.	2.5	23
110	The Inner Foreskin of Healthy Males at Risk of HIV Infection Harbors Epithelial CD4+ CCR5+ Cells and Has Features of an Inflamed Epidermal Barrier. PLoS ONE, 2014, 9, e108954.	2.5	27
111	Specificity and 6-Month Durability of Immune Responses Induced by DNA and Recombinant Modified Vaccinia Ankara Vaccines Expressing HIV-1 Virus-Like Particles. Journal of Infectious Diseases, 2014, 210, 99-110.	4.0	73
112	T-cell Responses Targeting HIV Env V2 in Natural Infection: Implications for RV144 Vaccine Recipients. AIDS Research and Human Retroviruses, 2014, 30, A179-A179.	1.1	0
113	Long-term Effect of Depot Medroxyprogesterone Acetate on Vaginal Microbiota, Epithelial Thickness and HIV Target Cells. Journal of Infectious Diseases, 2014, 210, 651-655.	4.0	82
114	Benefits of a comprehensive quality program for cryopreserved PBMC covering 28 clinical trials sites utilizing an integrated, analytical web-based portal. Journal of Immunological Methods, 2014, 409, 9-20.	1.4	20
115	Measuring inhibition of HIV replication by ex vivo CD8+ T cells. Journal of Immunological Methods, 2014, 404, 71-80.	1.4	12
116	Challenges and responses in human vaccine development. Current Opinion in Immunology, 2014, 28, 18-26.	5.5	60
117	Analysis of HLA A*02 Association with Vaccine Efficacy in the RV144 HIV-1 Vaccine Trial. Journal of Virology, 2014, 88, 8242-8255.	3.4	55
118	Optimization of a whole blood phenotyping assay for enumeration of peripheral blood leukocyte populations in multicenter clinical trials. Journal of Immunological Methods, 2014, 411, 23-36.	1.4	23
119	FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial. Journal of Clinical Investigation, 2014, 124, 3879-3890.	8.2	99
120	HIV-specific humoral responses benefit from stronger prime in phase Ib clinical trial. Journal of Clinical Investigation, 2014, 124, 4843-4856.	8.2	25
121	Efficacy Trial of a DNA/rAd5 HIV-1 Preventive Vaccine. New England Journal of Medicine, 2013, 369, 2083-2092.	27.0	518
122	HIV-1 Vaccine-Induced T-Cell Responses Cluster in Epitope Hotspots that Differ from Those Induced in Natural Infection with HIV-1. PLoS Pathogens, 2013, 9, e1003404.	4.7	39
123	Progress in HIV-1 vaccine development. Current Opinion in HIV and AIDS, 2013, 8, 1.	3.8	45
124	Vaccine-Induced Gag-Specific T Cells Are Associated With Reduced Viremia After HIV-1 Infection. Journal of Infectious Diseases, 2013, 208, 1231-1239.	4.0	73
125	OMIP ϵ 014: Validated multifunctional characterization of antigen ϵ -specific human T cells by intracellular cytokine staining. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2012, 81A, 1019-1021.	1.5	44
126	A Blueprint for HIV Vaccine Discovery. Cell Host and Microbe, 2012, 12, 396-407.	11.0	348

#	ARTICLE	IF	CITATIONS
127	Merck Ad5/HIV induces broad innate immune activation that predicts CD8 ⁺ T-cell responses but is attenuated by preexisting Ad5 immunity. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, E3503-12.	7.1	148
128	Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial. New England Journal of Medicine, 2012, 366, 1275-1286.	27.0	1,699
129	MRKAd5 HIV-1 Gag/Pol/Nef Vaccine-Induced T-Cell Responses Inadequately Predict Distance of Breakthrough HIV-1 Sequences to the Vaccine or Viral Load. PLoS ONE, 2012, 7, e43396.	2.5	30
130	Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccine. Journal of Clinical Investigation, 2012, 122, 359-367.	8.2	127
131	A Phase IIA Randomized Clinical Trial of a Multiclade HIV-1 DNA Prime Followed by a Multiclade rAd5 HIV-1 Vaccine Boost in Healthy Adults (HVTN204). PLoS ONE, 2011, 6, e21225.	2.5	131
132	Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial. Nature Medicine, 2011, 17, 366-371.	30.7	220
133	Standing Guard at the Mucosa. Immunity, 2011, 34, 146-148.	14.3	13
134	HIV-DNA Priming Alters T Cell Responses to HIV-Adenovirus Vaccine Even When Responses to DNA Are Undetectable. Journal of Immunology, 2011, 187, 3391-3401.	0.8	54
135	A Trimeric, V2-Deleted HIV-1 Envelope Glycoprotein Vaccine Elicits Potent Neutralizing Antibodies but Limited Breadth of Neutralization in Human Volunteers. Journal of Infectious Diseases, 2011, 203, 1165-1173.	4.0	71
136	Induction of Immunity to Human Immunodeficiency Virus Type-1 by Vaccination. Immunity, 2010, 33, 542-554.	14.3	239
137	<i>Ex Vivo</i> Comparison of Microbicide Efficacies for Preventing HIV-1 Genomic Integration in Intraepithelial Vaginal Cells. Antimicrobial Agents and Chemotherapy, 2010, 54, 763-772.	3.2	35
138	Immune Responses to HIV Vaccines and Potential Impact on Control of Acute HIV-1 Infection. Journal of Infectious Diseases, 2010, 202, S323-S326.	4.0	15
139	Safety and Immunogenicity of a Replication-Defective Adenovirus Type 5 HIV Vaccine in Ad5-Seronegative Persons: A Randomized Clinical Trial (HVTN 054). PLoS ONE, 2010, 5, e13579.	2.5	47
140	Setting the stage: host invasion by HIV. Nature Reviews Immunology, 2008, 8, 447-457.	22.7	456
141	Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet, The, 2008, 372, 1881-1893.	13.7	1,560
142	HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet, The, 2008, 372, 1894-1905.	13.7	670
143	Initial Events in Establishing Vaginal Entry and Infection by Human Immunodeficiency Virus Type-1. Immunity, 2007, 26, 257-270.	14.3	427
144	Defining blood processing parameters for optimal detection of cryopreserved antigen-specific responses for HIV vaccine trials. Journal of Immunological Methods, 2007, 322, 57-69.	1.4	206

#	ARTICLE	IF	CITATIONS
145	Optimization and validation of an 8-color intracellular cytokine staining (ICS) assay to quantify antigen-specific T cells induced by vaccination. <i>Journal of Immunological Methods</i> , 2007, 323, 39-54.	1.4	223
146	Effect of Combination Antiretroviral Therapy on Tâ€Cell Immunity in Acute Human Immunodeficiency Virus Type 1 Infection. <i>Journal of Infectious Diseases</i> , 2000, 181, 121-131.	4.0	148
147	HIV-1 Induces Cytotoxic T Lymphocytes in the Cervix of Infected Women. <i>Journal of Experimental Medicine</i> , 1997, 185, 293-304.	8.5	151
148	Studies of High Doses of a Human Immunodeficiency Virus Type 1 Recombinant Glycoprotein 160 Candidate Vaccine in HIV Type 1-Seronegative Humans. <i>AIDS Research and Human Retroviruses</i> , 1994, 10, 1713-1723.	1.1	60